Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6541
    +0.0018 (+0.28%)
     
  • OIL

    84.00
    +0.43 (+0.51%)
     
  • GOLD

    2,356.40
    +13.90 (+0.59%)
     
  • Bitcoin AUD

    98,398.52
    +780.27 (+0.80%)
     
  • CMC Crypto 200

    1,390.95
    -5.59 (-0.40%)
     
  • AUD/EUR

    0.6095
    +0.0022 (+0.36%)
     
  • AUD/NZD

    1.0975
    +0.0017 (+0.16%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,123.67
    +44.81 (+0.55%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,009.04
    +91.76 (+0.51%)
     
  • Hang Seng

    17,648.84
    +364.30 (+2.11%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Need To Know: Sisram Medical Ltd (HKG:1696) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look at whether insiders have been buying or selling shares in Sisram Medical Ltd (HKG:1696).

Do Insider Transactions Matter?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

ADVERTISEMENT

Insider transactions are not the most important thing when it comes to long-term investing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

Check out our latest analysis for Sisram Medical

Sisram Medical Insider Transactions Over The Last Year

While there weren't any large insider transactions in the last twelve months, it's still worth looking at the trading.

You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

SEHK:1696 Recent Insider Trading, September 15th 2019
SEHK:1696 Recent Insider Trading, September 15th 2019

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership of Sisram Medical

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From what we can see in our data, insiders own only about HK$474k worth of Sisram Medical shares. However, it's possible that insiders might have an indirect interest through a more complex structure. This level of insider ownership is notably low, and not very encouraging.

So What Does This Data Suggest About Sisram Medical Insiders?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Sisram Medical stock. To put this in context, take a look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow .

Of course Sisram Medical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.